%0 Journal Article
%T Nanomedicine Against A¦Â Aggregation by ¦Â¨CSheet Breaker Peptide Delivery: In Vitro Evidence
%J Pharmaceutics | An Open Access Journal from MDPI
%D 2019
%R https://doi.org/10.3390/pharmaceutics11110572
%X The accumulation of amyloid ¦Â (A¦Â) triggers a cascade of toxic events in Alzheimer¡¯s disease (AD). The KLVFF peptide can interfere with A¦Â aggregation. However, the peptide suffers from poor bioavailability and the inability to cross the blood¨Cbrain barrier. In this work, we study the possibility of adopting nanomedicine to overcome KLVFF limits in biodistribution. We produced new engineered polymeric nanoparticles (NPs), and we evaluated the cellular toxicity of these NPs and validated that KVLFF peptides released by NPs show the same promising effects on AD pathology. Our results revealed the successful generation of KVLFF loaded NPs that, without significant effects on cell heath, are even more potent in reversing A¦Â-induced pathologies compared to the free peptide. Therefore, NPs will significantly advance KVLFF treatment as a therapeutic option for AD
%U https://www.mdpi.com/1999-4923/11/11/572